Another study included persons with IBD ≥65 years, those on vedolizumab had a lower rate of infection-related hospitalizations (aHR: 0.47; 95% CI: 0.25, 0.86), compared to those on anti-TNF therapies (44). This evidence concerns the gene TNF and inflammatory bowel disease.